[A clinical study of thymosin alpha1 as an auxiliary in treating spontaneous peritonitis in patients with liver cirrhosis].

Plain Language Summary

This clinical study investigated thymosin alpha-1 as an auxiliary treatment for spontaneous bacterial peritonitis in patients with liver cirrhosis. The findings suggest a supportive role for this immune-boosting peptide in managing this serious infectious complication of advanced liver disease.